Compare LyondellBasell Industries NV (LYB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Smith & Nephew plc — how do they compare? LyondellBasell Industries NV trades at $60.28 (market cap $19.49B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays the higher dividend (4.57%). Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Smith & Nephew plc for 121 Days on average.
| LYB | SNN | |
|---|---|---|
Market Cap | $19.49B | $11.10B |
Volume | 6,033,396 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $37.17 |
52-Week Low | $42.28 | $26.42 |
Typical Hold Time | 87 Days | 121 Days |
Enterprise Value | $31.08B | $14.13B |
Dividend Yield | 4.57% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.90, up 4.12% today, with a bearish technical signal and mixed fundamentals. Revenue declined to $30.15B in 2025, with a net loss of $745M, though recent quarters show earnings beats. The stock is near its 52-week low, with key support at $60. Analyst consensus is split evenly between Buy and Hold, with a $69.38 price target. Recent news highlights dividend sustainability concerns amid chemical sector volatility.
Outlook remains cautious due to profitability challenges and high debt, but operational improvements and a 45% analyst buy rating suggest recovery potential. Risks include cyclical demand, margin pressure, and dividend coverage issues. The stock offers value at current levels if earnings stabilize, but investors should monitor cash flow trends and sector headwinds.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
